Tags

Type your tag names separated by a space and hit enter

A randomised double blind placebo controlled trial of fish oil in high risk pregnancy.
Br J Obstet Gynaecol 1995; 102(2):95-100BJ

Abstract

OBJECTIVE

To determine whether n-3 fatty acid (EPA/DCHA) prophylaxis is beneficial in high risk pregnancies.

DESIGN

A randomised, double blind, placebo controlled trial.

SETTING

Antenatal clinic of St James's University Hospital, Leeds.

SUBJECTS

Two hundred and thirty-three pregnant women at high risk of developing proteinuric or nonproteinuric pregnancy induced hypertension or asymmetrical intrauterine growth retardation.

INTERVENTION

Active treatment was 2.7 g of MaxEpa daily (1.62 g of eicosapentaenoic acid and 1.08 g of docosahexaenoic acid). Placebo were matching air-filled capsules.

MAIN OUTCOME MEASURES

Occurrence of proteinuric, nonproteinuric pregnancy induced hypertension or birthweight < 3rd centile.

RESULTS

There was no difference in an intention to treat analysis between the placebo and active treatment groups for occurrence of proteinuric pregnancy induced hypertension (relative risk (RR) = 0.88; 95% CI 0.47-1.66), nonproteinuric pregnancy induced hypertension (RR = 0.89; 95% CI 0.48-1.64), birthweight < 3rd centile (RR = 0.89; 95% CI 0.48-1.64), or the duration of pregnancy (difference of mean durations = 0.1 days; 95% CI -4.8 to 4.9 days). Analyses stratified by use of tobacco, and analyses excluding known major protocol violators gave essentially identical results.

CONCLUSION

There is no evidence from this study for any useful effect of fish oil supplementation for women at high risk of adverse outcomes from a pregnancy, but a small protective effect remains a possibility.

Authors+Show Affiliations

Department of Obstetrics and Gynaecology, St James's University Hospital, Leeds, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7756226

Citation

Onwude, J L., et al. "A Randomised Double Blind Placebo Controlled Trial of Fish Oil in High Risk Pregnancy." British Journal of Obstetrics and Gynaecology, vol. 102, no. 2, 1995, pp. 95-100.
Onwude JL, Lilford RJ, Hjartardottir H, et al. A randomised double blind placebo controlled trial of fish oil in high risk pregnancy. Br J Obstet Gynaecol. 1995;102(2):95-100.
Onwude, J. L., Lilford, R. J., Hjartardottir, H., Staines, A., & Tuffnell, D. (1995). A randomised double blind placebo controlled trial of fish oil in high risk pregnancy. British Journal of Obstetrics and Gynaecology, 102(2), pp. 95-100.
Onwude JL, et al. A Randomised Double Blind Placebo Controlled Trial of Fish Oil in High Risk Pregnancy. Br J Obstet Gynaecol. 1995;102(2):95-100. PubMed PMID: 7756226.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomised double blind placebo controlled trial of fish oil in high risk pregnancy. AU - Onwude,J L, AU - Lilford,R J, AU - Hjartardottir,H, AU - Staines,A, AU - Tuffnell,D, PY - 1995/2/1/pubmed PY - 1995/2/1/medline PY - 1995/2/1/entrez SP - 95 EP - 100 JF - British journal of obstetrics and gynaecology JO - Br J Obstet Gynaecol VL - 102 IS - 2 N2 - OBJECTIVE: To determine whether n-3 fatty acid (EPA/DCHA) prophylaxis is beneficial in high risk pregnancies. DESIGN: A randomised, double blind, placebo controlled trial. SETTING: Antenatal clinic of St James's University Hospital, Leeds. SUBJECTS: Two hundred and thirty-three pregnant women at high risk of developing proteinuric or nonproteinuric pregnancy induced hypertension or asymmetrical intrauterine growth retardation. INTERVENTION: Active treatment was 2.7 g of MaxEpa daily (1.62 g of eicosapentaenoic acid and 1.08 g of docosahexaenoic acid). Placebo were matching air-filled capsules. MAIN OUTCOME MEASURES: Occurrence of proteinuric, nonproteinuric pregnancy induced hypertension or birthweight < 3rd centile. RESULTS: There was no difference in an intention to treat analysis between the placebo and active treatment groups for occurrence of proteinuric pregnancy induced hypertension (relative risk (RR) = 0.88; 95% CI 0.47-1.66), nonproteinuric pregnancy induced hypertension (RR = 0.89; 95% CI 0.48-1.64), birthweight < 3rd centile (RR = 0.89; 95% CI 0.48-1.64), or the duration of pregnancy (difference of mean durations = 0.1 days; 95% CI -4.8 to 4.9 days). Analyses stratified by use of tobacco, and analyses excluding known major protocol violators gave essentially identical results. CONCLUSION: There is no evidence from this study for any useful effect of fish oil supplementation for women at high risk of adverse outcomes from a pregnancy, but a small protective effect remains a possibility. SN - 0306-5456 UR - https://www.unboundmedicine.com/medline/citation/7756226/A_randomised_double_blind_placebo_controlled_trial_of_fish_oil_in_high_risk_pregnancy_ L2 - http://www.diseaseinfosearch.org/result/5922 DB - PRIME DP - Unbound Medicine ER -